Skip to main content
Access Resources

MJFF Publications

3501 - 3510 of 7540 Results
Title
Year
  • Year
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • 2020
  • RESTRICTED
    Title: Dynamical system based compact deep hybrid network for classification of Parkinson disease related EEG signals
    Journal Name: Neural Networks
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.neunet.2020.06.018
    Best OA location URL:
    Citation Count: 49
  • RESTRICTED
    Title: Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism
    Journal Name: Neurotherapeutics
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s13311-020-00920-8
    Citation Count: 25
  • RESTRICTED
    Title: Evaluation of motor response inhibition in Parkinson's Disease and Alzheimer's Disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.06.314
    Best OA location URL:
    Citation Count: 0
  • RESTRICTED
    Title: Expert comment to: Novel Xp21.1 deletion associated with unusual features in large McLeod syndrome kindred
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2019.02.024
    Best OA location URL:
    Citation Count: 2
  • RESTRICTED
    Title: Exploring the clinical burden of OFF periods in Parkinson disease
    Journal Name: The American Journal of Managed Care
    Publisher: Managed Care and Healthcare Communications, LLC
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.37765/ajmc.2020.88517
    Best OA location URL:
    Citation Count: 8
  • RESTRICTED
    Title: Exposure-response efficacy model of apomorphine sublingual film for the on-demand treatment of “OFF” episodes in patients with Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.06.311
    Best OA location URL:
    Citation Count: 1
  • RESTRICTED
    Title: Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?
    Journal Name: Neurotherapeutics
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License: cc-by, cc-by
    DOI - Digital Object Identifier: 10.1007/s13311-020-00940-4
    Citation Count: 20
  • RESTRICTED
    Title: Getting ahead in the race for a cure: How nonprofits are financing biomedical R&D
    Journal Name: Research Policy
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.respol.2020.104032
    Best OA location URL:
    Citation Count: 3
  • RESTRICTED
    Title: If LRRK2 Set the Fire, Can Nonsteroidal Anti‐inflammatory Drugs Wet the Flames?
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28240
    Citation Count: 4
  • RESTRICTED
    Title: Impact of Levodopa/Carbidopa Intestinal Gel Delivery on CarePartner Burden and Quality of Life: Survey by Parkinson & Movement disorder alliance
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.06.325
    Best OA location URL:
    Citation Count: 0
Filters
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.